Document Type

Article

Publication Date

2022

Publication Information

36 Md. J. Int'l L. 14 (2022).

Abstract

I have a slightly different view from Dr. Oke in regard to his doubts regarding the utility of a waiver. To the extent that the precedent that we are looking at is whether or not there could be a waiver for countries that lack domestic manufacturing capabilities, to instead import a cheaper generic drug of the Covid vaccines that could be produced in other countries, mainly the particular hubs, such as in India and China, that is still an open question, and part of the proposal that is up before the TRIPS council involves that dimension and that aspect of the waiver as well.

Comments

Abstract from introduction.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.